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Background-—Chronic cardiotoxicity is less common in male than in female patients receiving doxorubicin and other
anthracyclines at puberty and adolescence. We hypothesized that this sex difference might be secondary to distinct activities of
sex hormones on cardiomyocyte senescence, which is thought to be central to the development of long-term anthracycline
cardiomyopathy.
Methods and Results-—H9c2 cells and neonatal mouse cardiomyocytes were exposed to doxorubicin with or without prior
incubation with testosterone or 17b-estradiol, the main androgen and estrogen, respectively. Testosterone, but not 17b-estradiol,
counteracted doxorubicin-elicited senescence. Downregulation of telomere binding factor 2, which has been pinpointed previously
as being pivotal to doxorubicin-induced senescence, was also prevented by testosterone, as were p53 phosphorylation and
accumulation. Pretreatment with the androgen receptor antagonist ﬂutamide, the phosphatidylinositol 3 kinase inhibitor
LY294002, and the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester abrogated the reduction in senescence and the
normalization of telomere binding factor 2 levels attained by testosterone. Consistently, testosterone enhanced the
phosphorylation of AKT and nitric oxide synthase 3. In H9c2 cells, doxorubicin-stimulated senescence was still observed up to
21 days after treatment and increased further when cells were rechallenged with doxorubicin 14 days after the ﬁrst exposure to
mimic the schedule of anthracycline-containing chemotherapy. Remarkably, these effects were also inhibited by testosterone.
Conclusions-—Testosterone protects cardiomyocytes against senescence caused by doxorubicin at least in part by modulating
telomere binding factor 2 via a pathway involving the androgen receptor, phosphatidylinositol 3 kinase, AKT, and nitric oxide
synthase 3. This is a potential mechanism by which pubescent and adolescent boys are less prone to chronic anthracycline
cardiotoxicity than girls. ( J Am Heart Assoc. 2016;5:e002383 doi: 10.1161/JAHA.115.002383)
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A nthracyclines are chemotherapeutic drugs used to treatseveral solid and hematological malignancies. A major
dose-limiting side effect of these compounds is cardiac
toxicity, which most often presents as subclinical myocardial
dysfunction or overt heart failure toward the end of
chemotherapy or later on, even after many years.1 This
delayed form of anthracycline cardiotoxicity is referred to as
chronic and has complex pathogenesis.2,3 It has been shown
recently that anthracyclines cause senescence of cardiomy-
ocytes.4 This event is central to the development of late-onset
anthracycline cardiomyopathy in mice5 and may be so in
humans.6
Female patients treated with anthracycline at puberty or
adolescence are more susceptible to chronic anthracycline
cardiotoxicity than male patients.7,8 Anthracyclines do not
accumulate in the adipose tissue; therefore, it has been
postulated that their clearance is lower—and the concentra-
tions reached in nonadipose organs, such as the heart, are
higher—in female patients than in male patients with the
same body surface area because the former have more fat
mass than the latter.8 Nevertheless, differences in the sex
hormone milieu might also account for the predisposition of
pubescent and adolescent girls to cardiac toxicity of anthra-
cyclines. In fact, left ventricular function and survival following
administration of doxorubicin, the prototype of anthracyclines,
are signiﬁcantly worse in mice knockout for the androgen
From the Laboratories of Cardiovascular Biology (P. Altieri, C. Barisione, E.L.,
G.P.B., M.C., P.S., C. Brunelli, and P. Ameri) and Cellular Therapies (A.G.),
Department of Internal Medicine, and Regenerative Medicine, Department of
Experimental Medicine (S.B.), University of Genova, Italy; Division of Internal
Medicine, Department of Translational Medical Sciences, Federico II University,
Napoli, Italy (C.G.T.).
Correspondence to: Pietro Ameri, MD, PhD, Laboratory of Cardiovascular
Biology, Department of Internal Medicine, Room 117, Viale Benedetto XV, 6,
16132 Genova, Italy. E-mail: pietroameri@unige.it
Received July 9, 2015; accepted November 22, 2015.
ª 2016 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.115.002383 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on January 10, 2016http://jaha.ahajournals.org/Downloaded from 
receptor (AR) than in controls, pointing to a protective role of
androgen against anthracycline cardiac damage.9
In this study, we compared the effect of testosterone and
17b-estradiol, the main androgen and estrogen, respectively,
on an established cell model of doxorubicin-induced senes-
cence of cardiomyocytes.10 After ﬁnding that testosterone, but
not 17b-estradiol, inhibited senescence elicited by doxoru-
bicin, we sought to characterize the relevant signaling pathway.
Methods
Unless otherwise indicated, all materials were supplied by
Sigma-Aldrich.
Animals
C57BL/6 breeders were purchased from Charles River
Research Models and Services (Lecco, Italy) and housed in
the animal facility of the IRCCS AOU San Martino—IST
National Institute for Cancer Research in Genova, Italy.
Primary mouse neonatal cardiomyocytes were isolated from
the hearts of pups aged 2 days. Procedures complied with
Italian national law concerning the use of animals for scientiﬁc
purposes and were approved by the institutional animal care
and use committee.
Cell Culture and Experimental Design
Experiments were carried out with H9c2 cells, and then
results were conﬁrmed with neonatal cardiomyocytes.
The rat embryonic cardiac cell line H9c2 was purchased
from the American Type Culture Collection (CRL-1446; Rock-
ville, MD), cultured as reported previously,11 and treated at a
density of 70% to 80%. These cells express the male-speciﬁc
gene sex-determining region Y (SRY) and have the testos-
terone metabolizing enzymes 5a-reductase and aromatase.12
Primary cardiomyocytes were obtained as described
previously, with minor modiﬁcations.13 Brieﬂy, hearts were
harvested, digested overnight in a 0.06% (wt/vol) solution of
trypsin (Gibco, Life Technologies), and further subjected to
multiple digestions with a 0.1% type II collagenase solution
(Worthington Biochemicals). Cells were preplated for 2
periods of 60 minutes each to enrich for cardiomyocytes
and subsequently cultured in DMEM containing 4.5 g/L
glucose supplemented with 10% FBS, 2 mmol/L L-glutamine,
and 100 U/mL penicillin. Purity of the culture was routinely
checked by immunoﬂuorescence with a monoclonal anticar-
diac troponin T antibody (clone 13-11; Thermo Fisher
Scientiﬁc), and each time at least 80% of cells were positive.
The complete culture medium was replaced with one with
0.5% FBS was added 1 hour before starting treatments, which
were also carried out in 0.5% FBS. Cells were exposed to
0.1 lmol/L doxorubicin (Adriblastina; Pﬁzer) for 3 hours10
with or without prior incubation with testosterone or 17b-
estradiol for 15 minutes. Both hormones were preliminarily
tested at different concentrations ranging from 0.1 to
1000 nmol/L (Figure 1). Testosterone was subsequently
used at 10 nmol/L because this dose maximally reduced
doxorubicin-induced senescence (Figure 1). Importantly,
10 nmol/L is within the normal values of circulating testos-
terone found in boys at puberty and adolescence.14 In girls at
the same age, physiological concentrations of 17b-estradiol
are around 1 nmol/L.14 Markers of senescence and telomere
binding factor 2 (TRF2) levels were evaluated 45 hours after
removing doxorubicin, whereas p53 was studied after
21 hours. The possibility of prolonged culturing of the H9c2
cell line was exploited to assess senescence over the long
term. Cells were challenged with 0.1 lmol/L doxorubicin as
in short-term experiments but then were maintained in
complete medium for 7, 14, or 21 days before determining
senescence. Furthermore, the effect on senescence of a
second 3-hour pulse of 0.1 lmol/L doxorubicin, given
14 days after the ﬁrst, was evaluated, as was the effect of
preincubation with testosterone.
To identify the intracellular mediators of testosterone
activity, cells were pretreated for 1 hour with the AR
antagonist ﬂutamide (10 lmol/L), the phosphatidylinositol 3
kinase (PI3K) inhibitor LY294002 (20 lmol/L; Calbiochem,
Merck), the p38 MAPK inhibitor SB203580 (10 lmol/L), and
the JNK inhibitor SP600125 (20 lmol/L); for 45 minutes with
the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine
methyl ester, L-NAME (1 mmol/L); or with relevant vehicles.
To analyze AKT and NOS-3 phosphorylation, cells were
preincubatedwith testosterone or left untreated for 15 minutes
followed by 20-minute exposure to doxorubicin or no treatment.
Assessment of Senescence
Three different features of senescence were investigated,
namely, enhanced b-galactosidase activity related to
increased lysosomal content, formation of heterochromatin
foci, and expression of the cell cycle inhibitor p16INK4a.15
Staining for senescence-associated (SA) b-galactosidase was
performed as described by Dimri et al,16 and positive cells
were counted out of total cells in 100 randomly chosen low-
power ﬁelds (9100). After staining for SA b-galactosidase,
0.13 mg/mL DAPI was added for 2 minutes at room
temperature to costain for SA heterocromatin foci.17 Immuno-
cytochemistry for p16INK4a was carried out as described
below. For each sample, images including a total of 300 cells
were taken randomly and digitized at 256 levels of gray. The
optical density of signals was measured with the Leica Q500
MC Image Analysis System.
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Western Blotting
Cells were lysed in lysis buffer (20 mmol/L Tris HCl [pH 7.5],
150 mmol/L NaCl, 1 mmol/L Na2-EDTA, 1 mmol/L EGTA, 1%
NP40, 2.5 mmol/L Na2P2O7, and 1 mmol/L b-glyceropho-
sphate). One mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/
L Na3VO4, 1 mmol/L NaF, and a protease inhibitor cocktail
(Thermo Fisher Scientiﬁc) were added to the buffer immedi-
ately before lysing.
The following primary antibodies were used (clones are
indicated for monoclonal antibodies): anti–phosphorylated
AKT (Ser473, clone D9E; Cell Signaling Technology), anti–
phosphorylated AKT (Thr308), anti-AKT (H-136), anti–phospho-
rylated NOS-3 (Ser1177, 15E2; Santa Cruz Biotechnology),
anti–NOS-3 (6H2; Cell Signaling Technology), anti-TRF2
(4S794.15; Imgenex, Novus Biologicals), anti–phosphorylated
p53 (Ser15, D4S1H; Cell Signaling Technology), anti-p53, anti-
GAPDH (FL-335), anti-AR (Millipore), and anti-ERK1/2. After
Figure 1. Effects of the studied concentrations of T and E2 on Dox-induced senescence of H9c2 cells.
Percentages (mean+SEM) of SA b-gal–positive H9c2 cells counted after no treatment or exposure to Dox
with or without prior incubation with T (A) or E2 (B) at the indicated concentrations. Group sizes: n=9 for no
treatment, Dox, and any concentration of T or E2 followed by Dox; n=6 for any concentration of T or E2
tested alone. Kruskal–Wallis P values are presented above each graph. Dunn’s multiple comparisons test:
*P<0.05, **P<0.01, ***P<0.005, and ****P<0.001 vs no treatment; #P<0.05, ##P<0.01, and ###P<0.005
vs Dox; §P<0.05 and §§P<0.01 vs T0.1; °P<0.05 vs T1. Dox indicates doxorubicin; E2, 17b-estradiol; SA
b-gal, senescence-associated b-galactosidase; T, testosterone.
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incubation with proper horseradish peroxidase–conjugated
secondary antibody (Santa Cruz Biotechnology), bands were
visualized with Clarity Western ECL Substrate (Bio-Rad) and
quantiﬁed by densitometry using an image analysis system
(UVItec). The quantity of phosphorylated AKT, NOS-3, and p53
was normalized for the amount of total protein. Levels of
GAPDH and ERK1/2, respectively, were used to normalize the
expression of TRF2 and p53 at 24 and 48 hours and the
expression of AR at 7, 14, and 21 days.
Immunocytochemistry
Cells were grown and treated on slides. At the end of
experiments, they were ﬁxed, permeabilized, and immunos-
tained for p16INK4a with a speciﬁc rabbit primary antibody
(Proteintech). Biotinylated secondary antibody (Vector), horse-
radish peroxidase–streptavidin (Vector), and 3,30-diaminoben-
zidine (DAB Peroxidase Substrate Kit; Vector) were used to
detect the bound primary antibody.18
Statistical Analysis
Results are presented as meanSEM of at least 3 independent
replicates. Because of the small sample sizes, comparisons
were drawn by Kruskal–Wallis followed by Dunn’s multiple
comparisons test. Statistical signiﬁcance was set at P<0.05.
Results
Testosterone Protects H9c2 Cells Against
Doxorubicin-Induced Senescence
The 3-hour treatment of H9c2 cells with doxorubicin signif-
icantly increased the percentage of senescent cells, as
assessed by staining for SA b-galactosidase (Figure 2A and
2C), p16INK4a (Figure 2B and 2C), and SA heterochromatin
foci (Figure 2D). Testosterone antagonized senescence eli-
cited by doxorubicin (Figure 2A through 2C). In contrast, 17b-
estradiol was not protective at either 100 nmol/L (Figure 2A
through 2C), for which biologically relevant actions have been
demonstrated,19 or any concentration tested (Figure 1).
Testosterone Inhibits Senescence Initiated by
Doxorubicin Through an AR/PI3K/AKT/TRF2
Pathway
We reasoned that a rapid, nongenomic mode of action
underlay the prevention of doxorubicin-triggered senescence
by testosterone because it was achieved by pretreating H9c2
cells for just 15 minutes. In particular, AR has been shown to
physically interact with PI3K, to enhance its activity, and to
promote AKT phosphorylation.20,21 Indeed, the AR antagonist
ﬂutamide and the PI3K inhibitor LY294002 abrogated the
reduction in cardiomyocyte senescence attained by testos-
terone (Figure 3). Conversely, the effect of testosterone was
not inﬂuenced by inhibition of p38 and JNK (Figure 3), despite
these kinases being involved in cardiomyocyte senescence
caused by doxorubicin.10 Western blotting demonstrated an
increase in phosphorylation of AKT at both Ser473 and Thr308
in H9c2 cells incubated with testosterone or testosterone and
then doxorubicin (Figure 4A through 4C).
Next we asked whether there was a link between the AR/
PI3K/AKT signaling cascade activated by testosterone and
TRF2. TRF2 is part of the telomere complex and contributes to
maintenance of telomeric integrity and function and to
suppression of the DNA damage response at the chromosome
ends.22 Our previous work identiﬁed its downregulation as a
key event in the pathogenesis of doxorubicin-elicited car-
diomyocyte senescence.10,23 Doxorubicin also induces p53
phosphorylation and accumulation,24 which also is involved in
telomere dysfunction triggered by doxorubicin in cardiomy-
ocytes.10 We conﬁrmed the reduction in TRF2 levels and the
increase in those of phosphorylated and total p53 following
incubation of H9c2 cells with doxorubicin and found that both
alterations were prevented by testosterone (Figure 4D
through 4F). The effect of testosterone on TRF2 was abolished
by pretreatment with ﬂutamide and LY294002 (Figure 4D
through 4F), indicating that it was dependent on AR and PI3K.
NOS-3 Is Implicated in Testosterone Prevention
of Doxorubicin-Triggered Senescence and TRF2
Downregulation
Consistent with previous studies,20 the activatory phosphory-
lation of NOS-3 at Ser1177 increased in response to testos-
terone in H9c2 cells in a PI3K-dependent manner (Figure 5A).
Because NOS-3/ mice have lower levels of TRF2 than wild
types,25 we considered the possibility that NOS-3 was
implicated in the signaling pathway linking testosterone to
the modulation of TRF2 and senescence. Indeed, pretreatment
of cells with the NOS inhibitor L-NAME reduced the ability of
testosterone to prevent doxorubicin-induced TRF2 downregu-
lation (Figure 5B) and senescence (Figure 5C).
Conﬁrmation of Results in Primary Neonatal
Cardiomyocytes
Testosterone substantially reduced doxorubicin-caused
senescence of primary mouse neonatal cardiomyocytes,
whereas 17b-estradiol was only marginally effective (Fig-
ure 6A and 6C). Protection of testosterone was lost when
cells were preincubated with ﬂutamide, LY294002, or L-NAME
but not with a p38 or JNK inhibitor (Figure 6B and 6C).
Moreover, testosterone almost normalized the expression of
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TRF2, and this effect was opposed by ﬂutamide and
LY294002 (Figure 6D).
Testosterone Inhibition of Doxorubicin-Initiated
Senescence is Long-Lasting
In agreement with our earlier ﬁndings,10 the prosenescent
response of H9c2 cardiomyoblasts to 3-hour treatment with
doxorubicin persisted over time. After being challenged with
doxorubicin, cells proliferated more slowly and were pas-
saged, on average, once a week compared with 2 or 3 times
per week for control. In addition, a higher number of treated
than control cells were positive for SA b-galactosidase after 7,
14, and 21 days (Figure 7A). Conversely, cells preincubated
with testosterone and then exposed to doxorubicin were split
twice a week and exhibited less SA b-galactosidase positivity
than those treated with doxorubicin only, with this effect
being AR dependent (Figure 7A).
Figure 2. T prevents Dox-elicited senescence of H9c2 cells. A, Percentage of SA b-gal–positive H9c2 cells
counted after no treatment or exposure to Dox with or without prior incubation with T or E2. B, Signal intensity
quantiﬁcation of the immunostaining for p16INK4a after the same treatments as in (A). C, Representative
images of the costaining for p16INK4a (brown) and SA b-gal–positive (blue) cells. Magniﬁcation is 9400, and
bars correspond to 50 lm. D, Representative pictures of Ctr or Dox-treated H9c2 cells costained for SA b-gal
(cytoplasmic, arrowheads) and heterochromatin foci (dots within the nucleus, arrows). Magniﬁcation91000,
bars 10 lm. Data in graphs are presented as means+SEM (7 and 4 observations for each SA b-gal and
p16INK4a group, respectively); Kruskal–Wallis P values are shown on top. Dunn’s multiple comparisons test:
*P<0.05 and ***P<0.005 vs no treatment. AU indicates arbitrary units; Ctr, control; Dox, doxorubicin; E2,
17b-estradiol; SA b-gal, senescence-associated b-galactosidase; T, testosterone.
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Figure 3. The androgen receptor/phosphatidylinositol 3 kinase/AKT pathway mediates T inhibition of Dox-
induced senescence of H9c2 cardiomyoblasts. A, Percentage of SA b-galactosidase–positive H9c2 cells counted
after no treatment or exposure to Dox with or without prior incubation with T, F and then T (F+T), LY and then T
(LY+T), SB and then T (SB+T), or SP and then T (SP+T). B, Signal intensity quantiﬁcation of the immunostaining for
p16INK4a after the same treatments as in (A). C and D, Representative pictures of H9c2 cells stained for SA b-gal (C)
and p16INK4a after no treatment or exposure to Dox with or without prior incubation with T, F and then T (F+T), LY
and then T (LY+T), SB and then T (SB+T), or SP and then T (SP+T). Magniﬁcation is 9200 in (C) and 9400 in (D);
bars correspond to 50 lm in both panels. Data in graphs are means+SEM (7 and 4 observations for each SA b-gal
and p16INK4a group, respectively); P values are from Kruskal–Wallis test. Dunn’s multiple comparisons test:
*P<0.05, **P<0.01, and ***P<0.005 vs no treatment. AU indicates arbitrary units; Ctr, control; Dox, doxorubicin; F,
ﬂutamide; LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); SA b-gal, senescence-associated b-galactosidase;
SB, SB203580 (p38 inhibitor); SP, SP600125 (JNK inhibitor); T, testosterone.
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To further gain insight into the prolonged protection
against doxorubicin cardiotoxicity conferred by testosterone,
H9c2 cells were incubated with doxorubicin once or twice in
2 weeks, with or without being pretreated with testosterone.
These experiments also allowed us to obtain data that were
more easily translatable to the clinical setting, in which
Figure 4. T stimulates AKT phosphorylation and prevents the changes in TRF2 and p53 levels caused by
doxorubicin. A through C, Representative western blots (A) and band densitometry (B and C) for
phosphorylated AKT in H9c2 cells preincubated with T or left untreated for 15 minutes followed by 20-
minute exposure to Dox or no treatment. D through F, Representative western blots (D) and band
densitometry (E through G) of TRF2 and p53 protein expression in H9c2 cells after no treatment or
exposure to Dox with or without prior incubation with T, F and then T (F+T), or LY and then T (LY+T). Data
are shown as means+SEM (3 observations per condition); P values are from Kruskal–Wallis test. Dunn’s
multiple comparisons test: **P<0.01 vs no treatment. Ctr indicates control; Dox, doxorubicin; F, ﬂutamide;
LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); p, phosphorylated; T, testosterone; TRF2, telomere
binding factor 2.
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Figure 5. NOS-3 is implicated in testosterone prevention of Dox-triggered downregulation of TRF2 and
senescence. A, Band densitometry and representative western blot for phosphorylated NOS-3 in H9c2
cells pretreated or not with LY and then incubated with T for 15 or 15+20 minutes, as indicated. B,
Representative western blot and band densitometry of TRF2 protein expression in H9c2 cells after no
treatment or exposure to Dox with or without prior incubation with T or LN and then T (LN+T). C,
Percentage of SA b-galactosidase–positive H9c2 cells counted after the same treatments as in (B). Data
are means+SEM. Western blot experiments included 3 replicates for each condition, whereas SA b-
galactosidase was assessed 4 times for no treatment and Dox and 7 times for T or LN+T followed by Dox.
Kruskal–Wallis P values are displayed above the graphs. Dunn’s multiple comparisons test: ****P<0.001
vs no treatment. Ctr indicates control; Dox, doxorubicin; LN, L-NG-nitroarginine methyl ester, or L-NAME;
LY, LY294002 (phosphatidylinositol 3 kinase inhibitor); NOS, nitric oxide synthase; p, phosphorylated; SA
b-gal, senescence-associated b-galactosidase; T, testosterone; TRF2, telomere binding factor 2.
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Figure 6. T inhibits Dox-caused senescence of primary neonatal cardiomyocytes via androgen
receptor/phosphatidylinositol 3 kinase/nitric oxide synthase 3. A and B, Percentage of SA b-gal–
positive primary mouse neonatal cardiomyocytes after no treatment or exposure to Dox with or
without prior incubation with T or E2 (A) or T, F and then T (F+T), LY and then T (LY+T), LN and then T
(LN+T), SB and then T (SB+T), or SP and then T (SP+T) (B). C, Representative pictures of the staining
for SA b-gal after the same treatments as in (A) and (B). Magniﬁcation is 9200, and bars
correspond to 50 lm. D, Representative western blot and band densitometry of TRF2 protein
expression in primary mouse neonatal cardiomyocytes after no treatment or exposure to Dox with
or without prior incubation with T, F and then T (F+T), or LY and then T (LY+T). Means+SEM and
Kruskal–Wallis P values are shown in graphs (western blots: 3 observations per group; SA b-gal: 7
assessments for no treatment, Dox, and T or E2 followed by Dox; 4 for all the other conditions).
Dunn’s multiple comparisons test: *P<0.05, **P<0.01, ***P<0.005, and ****P<0.001 vs no
treatment; #P<0.05 vs Dox. Ctr indicates control; Dox, doxorubicin; E2, 17b-estradiol; F, ﬂutamide;
LN, L-NG-nitroarginine methyl ester, or L-NAME (nitric oxide synthase inhibitor); LY, LY294002
(phosphatidylinositol 3 kinase inhibitor); SA b-gal, senescence-associated b-galactosidase; SB,
SB203580 (p38 inhibitor); SP, SP600125 (JNK inhibitor); T, testosterone; TRF2, telomere binding
factor 2.
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patients receive cycles of anthracycline-containing
chemotherapy regimens every 2 or 3 weeks. Two pulses of
doxorubicin 14 days apart caused senescence of H9c2
cardiomyoblasts in an additive manner (Figure 7B).
Pretreatment with testosterone before each incubation
with doxorubicin decreased the percentage of SA
b-galactosidase–positive cells. Furthermore, senescence
was reduced, albeit to a slightly lesser extent, when only
the second pulse of doxorubicin was preceded by testos-
terone (Figure 7B). These results prompted us to investigate
the expression of AR, which had proved to be necessary for
testosterone action, over the 21 days of culturing. Surpris-
ingly, and unlike observations at 24 and 48 hours (Figure 4D
through 4F), GAPDH protein expression was substantially
reduced by doxorubicin at 7, 14, and 21 days (Figure 8).
Consequently, the expression of AR was normalized against
that of ERK1/2, which did not vary throughout the
experiment. At every time point, levels of AR were signif-
icantly lower in doxorubicin-treated cells than in control cells
and were partially restored by preincubation with testos-
terone via AR (Figure 8).
Discussion
Senescence of cardiac cells is considered to be of primary
importance for the occurrence of anthracycline-related car-
diomyopathy.26 Doxorubicin induces a senescent-like pheno-
type in cardiomyocytes, with an abnormal pattern of troponin
phosphorylation that may lead to inefﬁcient cardiac contrac-
tion.4 Moreover, doxorubicin causes senescence of resident
cardiac progenitor cells (CPCs), which preserve myocardial
tissue homeostasis following stress.27 It has been proposed
that senescence of CPCs in response to doxorubicin may be
especially relevant at a young age because CPCs may no
longer be able to activate a repair program for minor cardiac
injuries, which therefore build up until they irreversibly affect
cardiac structure and function.6 In fact, mice injected with
doxorubicin shortly after birth have normal hearts as adults
but exhibit pathological eccentric hypertrophy following
endurance training and more extensive myocardial infarction
than wild-type littermates after coronary artery ligation, along
with fewer, less proliferating, and less differentiating CPCs.5
In the present work, we found that testosterone antago-
nized doxorubicin-initiated senescence of both H9c2 cells and
primary neonatal cardiomyocytes, whereas the effectiveness
of 17b-estradiol was poor. This new information integrates
the previous demonstration that AR deletion enhances
cardiomyocyte apoptosis, cardiac remodeling, and mortality
caused by doxorubicin in mice.9 Moreover, it substantiates
the hypothesis that differences in sex hormones may explain,
at least in part, the higher risk of left ventricular dysfunction
and heart failure that has been demonstrated in female
survivors of cancer in puberty and adolescence who were
treated with anthracycline.7,8,28 It is possible that pharma-
cokinetic factors also contribute to the young female
predisposition to anthracycline cardiotoxicity. The uptake of
anthracyclines by adipose tissue is lower than by other
organs.29 Consequently, the higher the fat mass, the higher
the concentration of anthracyclines in the bloodstream and in
nonadipose tissues, including the heart.30,31 Anthracyclines
are dosed based on body surface area, but from puberty and
thereafter, female patients generally have higher percentages
of body fat than male patients, thus they might be more
susceptible to cardiac side effects of anthracyclines.28
No clear sex difference in the incidence of anthracycline-
related cardiotoxicity has been found in the adult oncological
population. This may be due to the fact that anthracycline-
based chemotherapies are most often given for breast cancer,
which almost exclusive for the female sex. Nevertheless, the
paradigm that androgen confers an advantage against
cardiotoxicity of doxorubicin may be not valid in adulthood
because estrogen during fertile age favorably inﬂuences
cardiovascular risk factors and has direct beneﬁcial activity on
the heart.
Figure 7. T protection against Dox-stimulated senescence is
long-lasting. A, Percentage of SA b-gal–positive H9c2 cells
counted 7, 14, and 21 days after no treatment or exposure to
Dox, with or without prior incubation with T or F and then T (F+T).
B, Percentage of SA b-gal–positive H9c2 cells counted after
treating 15 days apart with Dox and/or T, as indicated. Graphs
display means+SEM (5 observations per group) and Kruskal–
Wallis P values. Dunn’s multiple comparisons test: *P<0.05 vs no
treatment. Ctr indicates control; Dox, doxorubicin; F, ﬂutamide;
SA b-gal, senescence-associated b-galactosidase; T, testosterone.
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Telomere dysfunction is a well-established cause of
senescence.32 In a landmark paper, Maejima and colleagues
showed that primary neonatal cardiomyocytes display mark-
ers of senescence and reduced telomerase activity on
incubation with doxorubicin.4 Expanding their observations,
we previously demonstrated that TRF2 levels are decreased
by treatment with doxorubicin and that silencing of Terf2 is
sufﬁcient to trigger senescence in H9c2 cells and neonatal
cardiomyocytes.10 Subsequent studies have revealed that
doxorubicin also induces senescence of vascular smooth
muscle cells by downregulating TRF2.33 In this study, it was
shown that inhibition of doxorubicin-elicited senescence by
testosterone is paralleled by the normalization of TRF2
expression, suggesting that prevention of TRF2 imbalance
and telomeric dysfunction is at least 1 of the mechanisms by
which testosterone counteracts cardiomyocyte senescence
secondary to doxorubicin exposure.
Testosterone acts via AR, a steroid hormone receptor that
classically works as a ligand-activated transcription factor, but
it can also localize to the plasma membrane and initiate
nongenomic signaling cascades.34 In cardiomyocytes, this
modality of action has already been reported, for example, for
the modulation of intracellular calcium concentrations35 and
action potential duration20 or for the stimulation of hypertro-
phy.36 This study provides evidence that antagonism of
doxorubicin-induced senescence and TRF2 downregulation is
another nongenomic effect of testosterone and that it occurs
through a signaling pathway involving PI3K, AKT, and NOS-3.
Activation of AKT has repeatedly been linked to inhibition
of senescence in cardiovascular cells.25,37–40 In addition,
Ser473 phosphorylation of AKT is decreased in senescent
CPCs.41 Interestingly, phosphorylation of AKT at this site has
speciﬁcally been related to cardioprotection against doxoru-
bicin, which is enhanced when PH domain leucine-rich repeat
protein phosphatase 1, which selectively dephosphorylates
AKT at Ser473, is knocked down.42 Furthermore, AKT activa-
tion has been associated with TRF2 induction and PI3K or AKT
inhibition with diminished TRF2 levels in endothelial cells.40
Based on the fact that NOS-3 is a downstream target of the
AR/PI3K/AKT signal transduction cascade in cardiomy-
ocytes20 and on the ﬁnding that protection by testosterone
was attenuated by pretreatment with L-NAME (Figure 5), we
propose that NOS-3 mediates androgen modulation of TRF2
and antagonism of doxorubicin-stimulated senescence. In
addition to the AR/PI3K/AKT/NOS-3 cascade, however,
other nongenomic cascades may underlie testosterone reg-
ulation of TRF2 and senescence. Nitric oxide release by NOS-
3, for example, has recently been demonstrated to reduce
H2O2-induced senescence of H9c2 cells by improving redox
state.43
In apparent discordance with our results, mice knockout
for NOS3 are less sensitive to doxorubicin-triggered cardiac
cell apoptosis, intramyocardial production of reactive oxygen
species, left ventricular dysfunction, and death. Furthermore,
cardiomyocyte-speciﬁc overexpression of NOS3 exacerbates
cardiac toxicity of doxorubicin.44,45 This phenotype has been
ascribed to the involvement of NOS-3 in the so-called redox
cycling of anthracyclines, namely, the reduction to semiqui-
none radicals that then react with oxygen and undergo
oxidation with generation of superoxide anion. In contrast,
another NOS isozyme, NOS-1, is overexpressed in NOS-3
knockouts, and it has been suggested that NOS-1 might
actually be responsible for the resistance to doxorubicin
cardiac damage associated with NOS3 deletion.45 Conse-
quently, NOS activity may be generally protective against
doxorubicin cardiotoxicity although with differences in the
involved isoform, depending on the experimental model.
We observed the most intense decrease in doxorubicin-
initiated senescence of cardiomyocytes with 10 nmol/L
Figure 8. Effect of Dox on AR expression in H9c2 cells.
Representative western blots and band densitometries (mean+-
SEM, 3 observations per group) of AR protein expression in H9c2
cells 7, 14, and 21 days after no treatment or exposure to Dox,
with or without prior incubation with T or F and then T (F+T).
Kruskal–Wallis P values are shown above each graph. Dunn’s
multiple comparisons test: *P<0.05 vs Ctr. AR indicates androgen
receptor; Ctr, control; Dox, doxorubicin; F, ﬂutamide; T, testos-
terone.
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testosterone, which is well within the range of normal plasma
values for pubescent and adolescent boys.14 Inhibition of
senescence was not as strong with 100 nmol/L, a supra-
physiological concentration of testosterone,14 and was lost
with 1000 nmol/L testosterone, which is a very high dose.
This latter dose may no longer be able to activate antisenes-
cence pathways, similar to what has been reported previously
for the modulation of calcium transients by testosterone,35 or
it may stimulate signaling cascades that oppose those
preventing doxorubicin-induced senescence. In any case, it
should be noted that important variations in doxorubicin and
testosterone metabolism and action likely exist between cell
cultures and the whole human body.
In our experiments, doxorubicin after testosterone differ-
ently inﬂuenced the phosphorylation status of Ser473 and
Thr308 of AKT. There are several possible reasons for this
phenomenon, including doxorubicin modulation of the activity
of AKT kinases and phosphatases and of the interaction
between AKT and its binding proteins. Nevertheless, it should
be kept in mind that the effect of doxorubicin on AKT
phosphorylation appears to be importantly affected by the
experimental setting, up to the point that opposite results
have been obtained with the same animal model.46,47
Doxorubicin persistently downregulated AR protein in H9c2
cardiomyoblasts, and pretreatment with testosterone partially
rescued its expression, possibly allowing androgen contained
in the culture medium to antagonize senescence triggered by
doxorubicin. Strikingly, a reduction in GAPDH protein expres-
sion was also observed during prolonged culturing. It is known
that doxorubicin causes profound posttranslational modiﬁca-
tions to proteins,48 among which may be AR and GAPDH.
Nonetheless, this is speculation, and future investigations are
needed to characterize the modulation of AR and GAPDH by
doxorubicin and the mechanism behind it.
The present study has limitations that must be acknowl-
edged. First, it is possible that androgen is also protective
against doxorubicin-initiated senescence via canonical geno-
mic pathways, and this was not addressed by our exper-
iments. Similarly, it cannot be excluded that 17b-estradiol
also promotes the transcription of genes that counteract
doxorubicin toxicity and/or senescence. Second, doxorubicin
affects many other cellular events that have been not
analyzed in this study, such as apoptosis and autophagy,
and that might be inﬂuenced by sex hormones. Third, further
studies speciﬁcally using CPCs are needed because they are
thought to be pivotal in anthracycline cardiotoxicity. Finally, it
remains to be proven in vivo that inhibition of cardiomyocyte
and possibly CPC senescence by testosterone actually
translates into reduced incidence or severity of anthracycline
cardiomyopathy.
In conclusion, this work offers a biological explanation for
the relative resistance of the male heart to anthracycline
toxicity. In general, it adds to the knowledge of the
cardiovascular effects of testosterone and may form the
basis for additional research into the role of this hormone in
stress-induced senescence of cardiac cells.
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